Last week, a big biotech company announced that it’s spinning off a smaller company. Illumina is a DNA sequencing giant, and Grail is its ambitious child. Grail aims to spot cancer early by detecting genetic changes in blood of apparently healthy people.
I admire the goal of early cancer detection, but think this a fool’s mission.
